Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
· Data readout demonstrates a significantly superior capacity of imlifidase to rapidly reduce levels of donor-specific antibodies (DSAs) compared to plasma exchange (standard of care) in the five days following the start of the treatment. · A total of 30 patients have been randomized 2:1 to either imlifidase or plasma exchange with a six-month follow up period.[1] · These first results are an important milestone in executing on Hansa’s strategy to expand the reach of its IgG antibody cleaving technology platform to address significant unmet medical needs in a wide spectrum of disease